Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
209 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape. H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 7, 7, 1, 47, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 2, 1, 11 and 3 molecules, respectively. Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Influenza A Virus, H1N1 Subtype Infections - Overview 6 Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development 7 Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 21 Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 29 Influenza A Virus, H1N1 Subtype Infections - Drug Profiles 50 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 182 Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 185 Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 186 Appendix 198
List of Tables
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by ContraFect Corp, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by iBio Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by MedImmune LLC, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mucosis BV, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Touchlight Genetics Ltd, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova AB, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Visterra Inc, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017 Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
